Norflurazepam Blister 10x 10mg research tablets in blister packaging
Norflurazepam Blister - 10x 10mg Price range: € 20,90 through € 198,75
Back to products

Norflurazepam Blister – 10x 5mg

Price range: € 15,90 through € 163,75

Norflurazepam Blister 10x 5mg is described as a research product containing N-desalkylflurazepam, a 1,4-benzodiazepine and active metabolite of flurazepam.

The reported presentation consists of ten blister-packed tablets, each with a nominal ingredient-content claim of 5 mg.

The supplied CAS number is 2792-23-8, pending verification.

The source provides molecular formula C15H11ClFN3O and molecular weight 303.72 g/mol. Although internally consistent, these values do not match the commonly described neutral structure of N-desalkylflurazepam.

The source claims at least 98% ingredient purity, independent laboratory testing, batch traceability, and finished-tablet uniformity assessment.

No actual batch-specific Certificate of Analysis or finished-tablet assay was supplied.

The actual ingredient identity, tablet content, excipients, impurity profile, and storage stability remain unverified.

Norflurazepam is associated with clinically significant benzodiazepine hazards, including sedation, dependence, and respiratory depression, particularly when combined with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12524 Category:
Description

Norflurazepam Blister 10x 5mg – Research Material Information

Norflurazepam Blister 10x 5mg – Product Overview

Norflurazepam Blister 10x 5mg is the supplied catalog designation for blister-packed research tablets described as containing N-desalkylflurazepam.

The source specifies ten tablets per blister, with a nominal ingredient content of 5 mg per unit.

This is a label claim rather than an independently verified finished-product assay.

The source describes the material as intended for controlled laboratory investigation involving chemical identity, analytical documentation, and comparative characterization of benzodiazepine metabolites.

No actual Certificate of Analysis, content-uniformity report, or batch-specific analytical record was supplied.

The material is not established as a certified reference standard or approved pharmaceutical product.

Chemical Identity & Classification

Norflurazepam, also known as N-desalkylflurazepam, is a 1,4-benzodiazepine associated with the metabolism of flurazepam.

The source reports:

  • Product designation: Norflurazepam Blister 10x 5mg
  • Reported CAS number: 2792-23-8
  • Supplied molecular formula: C15H11ClFN3O
  • Supplied molecular weight: 303.72 g/mol
  • Reported presentation: Blister-packed tablets
  • Nominal ingredient content: 5 mg per tablet
  • Nominal pack quantity: 10 tablets
  • Intended designation: Research Use Only

The supplied formula and molecular weight are internally consistent.

However, the commonly described neutral N-desalkylflurazepam structure corresponds to C15H10ClFN2O, with calculated molecular weight approximately 288.71 g/mol.

The discrepancy must be resolved before definitive molecular specifications are published.

The source-provided CAS number also requires independent verification.

Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the actual compound.

Chemical & Physical Characteristics

The source describes compressed tablets enclosed in tamper-evident blister packaging.

No actual finished-product inspection record, packaging-validation report, or tablet specification was supplied.

The source does not establish tablet dimensions, hardness, disintegration characteristics, or excipient composition.

It also does not establish whether the reported material contains the neutral compound or another chemical form.

The source refers to analytical stability and physical integrity, but no validated finished-product stability study was provided.

Blister packaging does not independently establish long-term protection from light, moisture, or other environmental conditions.

Purity & Analytical Verification

The source claims ingredient purity of at least 98% by HPLC.

It also refers to analytical identity confirmation using HPLC, mass spectrometry, and NMR spectroscopy.

No actual chromatogram, mass spectrum, NMR spectrum, impurity profile, or batch-specific Certificate of Analysis was supplied.

The claimed purity therefore remains unverified.

Ingredient purity and finished-tablet content are separate measurements.

A reported ingredient purity of 98% does not establish that each tablet contains 5 mg of norflurazepam.

The source describes analytical applications involving LC-MS/MS and other laboratory techniques.

These descriptions do not demonstrate that a particular analytical method has been validated for the supplied product.

No certified reference-material documentation, assigned reference value, or metrological traceability record was supplied.

Quality Control & Batch Integrity

The source claims third-party laboratory testing, batch traceability, content-uniformity assessment, and controlled manufacturing.

No independent testing report, manufacturing record, finished-tablet assay, or content-uniformity dataset was supplied.

The claims therefore remain unverified.

For a finished-tablet product, ingredient identity, ingredient purity, tablet mass, and actual ingredient content must be distinguished.

Relevant documentation may also include excipient information, batch identifiers, residual-solvent findings, and available stability records.

The Research Use Only designation does not independently establish quality certification or quantitative analytical performance.

Safety, Handling & Laboratory Precautions

Norflurazepam is a pharmacologically active benzodiazepine associated with central nervous system depression.

Potential hazards include pronounced sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.

Combining benzodiazepines with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.

The source does not include a verified product-specific Safety Data Sheet.

Institutional safety procedures should address restricted access, appropriate protective equipment, accidental-exposure response, contamination prevention, secure custody, and waste management.

The tablet and blister presentation must not be interpreted as evidence of suitability for human administration.

Packaging, Labeling & Storage

The source describes one blister containing ten tablets, each nominally labeled as containing 5 mg norflurazepam.

The total nominal labeled ingredient quantity is therefore 50 mg per blister.

This is an arithmetic total based on the supplied label claims, not an independently verified analytical result.

The source recommends cool, dry storage and suggests a temperature range of approximately 2–8°C.

No validated stability study was supplied to establish that range as a confirmed storage requirement.

No packaging-performance documentation was supplied to establish long-term protection against environmental degradation.

Intended Research Use & Market Positioning

The supplied material describes laboratory contexts involving benzodiazepine chemical identity, structural characterization, and analytical documentation.

No certified reference-material status or validated quantitative performance has been demonstrated.

The supplied Raw Lab Chems catalog references include Norflurazepam Powder, Norflurazepam Pellets 5mg, and Norflurazepam Blister 10x 5mg.

These entries describe different product presentations.

Their chemical identity, formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.

Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.

Ordering, Availability & Fulfillment

The source claims international shipping, tracking, customs documentation, and compliant transport.

No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.

The source also refers to IATA and DOT compliance.

No applicable dangerous-goods classification, transport assessment, or supporting compliance documentation was provided.

No claim is therefore made that worldwide shipment or customs clearance is universally available or legally authorized.

Norflurazepam may be controlled or otherwise restricted under applicable national and international laws.

Research-only labeling does not establish a legal exemption.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Norflurazepam is a benzodiazepine compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.

Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified analytical status is implied.

Additional information
Quantity

2

,

5

,

10

,

25

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Norflurazepam Blister – 10x 5mg”
Shipping & Delivery